Trafalgar Charter Rewrite Kills 481M Conversion Shares, Locks In 51% Series B Control
TRFA is trading near its 52-week low of $0.75 (0.0% above the low) on elevated volume (3.2× avg).
Summary
Trafalgar's definitive information statement details a charter restatement, already approved by written consent, that eliminates 481.4M potential common shares from preferred conversion while granting the controlling Series B holder at least 51% of fully diluted voting power.
Key Events · Corporate Governance and Compliance · TRFA
-
Charter Restatement Eliminates Conversion Overhang
Series A and Series B conversion rights are permanently extinguished, removing 481,433,250 potential common shares — 381,433,250 from Series A at 50-for-1 and 100,000,000 from Series B at 100,000-for-1 — versus 199,153 common shares outstanding.
-
Series B Locks In 51% Voting Control
Series B becomes nonconvertible but holds at least 51% of aggregate voting power on a fully diluted basis, recalculated automatically as the voting base changes, plus protective consent rights over charter amendments, mergers and dilutive voting securities.
-
Series A Stripped Of Rights
The 7,628,665 outstanding Series A shares lose their 1.76-vote-per-share general voting rights, liquidation preference and dividend entitlement, and are no longer convertible.
-
Approved By Written Consent, No Vote
Trafalgar Asset Management, LLC, holder of 99.28% of aggregate voting power, consented on the October 12, 2026 record date; no shareholder meeting or proxy is being held and no dissenters' rights apply.
Analysis · TRFA · Life Sciences
The restatement permanently eliminates the preferred conversion mechanisms that could have produced 481,433,250 common shares — 381,433,250 from the 7,628,665 Series A shares at 50-for-1 and 100,000,000 from the 1,000 Series B shares at 100,000-for-1 — against only 199,153 common shares currently outstanding. That removes a massive overhang, but the trade is control: Series B becomes a nonconvertible series entitled to at least 51% of fully diluted voting power, held entirely by Trafalgar Asset Management, LLC, which already carries 99.28% of aggregate voting power. Common holders get no appraisal rights and no vote, since the action was taken by written consent. The 2,000,000,000 authorized common shares and 20,000,000 authorized preferred shares leave enormous room for future issuance, so the dilution risk shifts from the old conversion formulas to board discretion.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRFA was trading at $0.75 on OTC in the Life Sciences sector, with a market capitalization of approximately $149.4K. The 52-week trading range was $0.75 to $50,619.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.